Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that topical patidegib gel significantly shrank basal cell carcinomas in Gorlin syndrome patients without causing the systemic side effects common with oral hedgehog inhibitors.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

This study found that 18-β-Glycyrrhetinic acid, a licorice component, stimulated human hair follicle cell proliferation, inhibited testosterone 5α-reductase, and suppressed TGF-β1, suggesting potential for treating androgenetic alopecia by promoting hair growth and prolonging the anagen phase.

This study suggests that edelweiss extract may promote hair growth and reduce shedding in ex vivo experiments by affecting hair follicle anagen phase duration and keratinocyte proliferation.

In this study, oral spermidine supplementation was found to significantly prolong the hair follicle anagen phase and reduce hair loss, with effects persisting three months after treatment in healthy participants, suggesting potential therapeutic benefits for hair loss conditions.

This study identified a distinct "exogen" phase in the hair cycle during which hair shedding occurs, primarily coupled with the anagen phase, rather than as part of the telogen phase.

In this study, lipid peroxides were found to induce apoptosis in hair follicle cells and advance the catagen phase in mice, suggesting a potential mechanism for alopecia development.

This study suggests that new cells are incorporated into the dermal papilla during the early anagen phase of the hair cycle, which may influence hair growth consistency and follicle size changes.

In this study, adenosine was found to stimulate hair follicle growth in vitro by promoting growth factor expression, β-catenin activation, and downstream signaling pathways.

This study found that telogen, a resting phase of the hair follicle cycle, is characterized by dynamic gene expression, including enhanced cholesterol metabolism and immune signaling, suggesting it is an active regulatory phase despite its quiescent appearance.

This study found that Polygonum multiflorum extract may promote hair growth by increasing anagen duration and activating dermal papilla cells in human hair follicles, as observed in cultured cell models.

TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.

The authors concluded that utilizing clock gene expression from hair follicle cells may improve circadian-phase estimation in clinical settings, aiding the detection of circadian-related sleep problems despite social time constraints.

This article discusses using high performance liquid chromatography to optimize mobile phase composition for separating synthesis products of Finasteride, without reporting new clinical results.

This study found that a spermidine-based nutritional supplement increased the number of anagen phase hair follicles in healthy humans, suggesting potential benefits for hair loss conditions.

This study suggests that Eclipta prostrata may promote hair growth in mice and human dermal papilla cells through regulating FGF-7 and mTOR signaling.

In this study, γ-ray irradiation of mice reduced hair follicle density and pigmentation, suggesting damage to stem cells and progenitors for keratinocytes and melanocytes.

In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.

This study found that CARI ONE, a herbal mixture, promotes hair growth in mice by inducing the transition from telogen to anagen phase and enhancing hair follicle development, compared to control and minoxidil treatments.

This study found that the Spanish version of the hair-specific Skindex-29 questionnaire effectively detected changes in health-related quality of life among women with female-pattern hair loss, and the scores were significantly correlated with the SF-12 survey results after treatment with a 5 alpha-reductase inhibitor.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study found that therapy significantly reduced serum IgM levels in dogs with severe dermatitis, but not in those with mild dermatitis, highlighting the effect of treatment on immune response in severe cases.

This study found that dermal injection of M-CSF stimulated CD11b + myeloid cells can induce alopecia areata in mice by potentially activating B lymphocytes, offering insight into the disease's pathogenesis.

In this study, using Trichosol™ with Minoxidil (3%) increased the percentage of hair in the anagen growth phase by about 20% over 90 days compared to using Minoxidil alone.

This study found that hair damage from sunlight and chemical processes like perms and bleaching varies in internal microstructure changes, suggesting that protective techniques should be tailored to the type of chemical treatment used.

This technical report from the European Food Safety Authority responds to comments on its previous scientific opinion regarding a health claim about spermidine and hair growth, reporting no new experimental results.

This study found that the BMP antagonist noggin induces hair growth in postnatal skin by neutralizing BMP4's inhibitory activity, potentially mediated by changes in Shh expression.

This study found that cystatin M/E strongly inhibits human cathepsin V and cathepsin L via distinct non-overlapping sites, suggesting an important role in human epidermal differentiation and hair follicle morphogenesis.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.